HRT can relieve scores of midlife symptoms beyond hot flushes, doctors say

Women experiencing a range of persistent midlife problems — from recurrent urinary infections and joint pain to headaches and heart palpitations — may benefit from hormone replacement therapy (HRT) even if they do not report classic hot flushes, clinicians and recent commentary suggest.

Hormonal changes in the perimenopause and menopause, typically occurring between ages 45 and 55, are associated with falling levels of oestrogen and progesterone. That decline can cause thinning and drying of vulvovaginal and urethral tissue, increasing susceptibility to urinary tract infections, and has been linked in medical literature to more than 30 symptoms including musculoskeletal pain, headaches, dizziness, palpitations, low libido and cognitive fog.

Physicians say recognition of these varied presentations matters for diagnosis and treatment. In some cases the appropriate form of HRT — such as topical vaginal oestrogen for urinary and genitourinary symptoms — can reduce infection frequency and relieve local soreness. Systemic HRT delivered by tablets, patches or gels can address broader symptoms tied to falling oestrogen levels.

The use of HRT on Britain’s National Health Service has increased markedly in the past decade, from roughly 1 million users to about 2.6 million, reflecting growing awareness and changing prescribing patterns. At the same time, public conversations on social media and in celebrity interviews have highlighted benefits beyond hot flushes, prompting some clinicians to warn against both overgeneralisation and undue dismissal.

"Not every midlife symptom is hormonal," said clinicians who advise patients to pursue evaluation. Work stress, thyroid disease, anaemia and other conditions can cause identical complaints. There is no single laboratory test that confirms suitability for HRT; diagnosis and treatment decisions are clinical and made in consultation with a general practitioner or specialist.

Medical literature and clinical experience suggest several symptom patterns that should prompt consideration of a hormonal contribution. Joint and connective tissue pain that begins or worsens in midlife can reflect oestrogen loss, because the hormone plays a role in maintaining joint health. Headaches and migraine patterns sometimes shift with hormonal fluctuations. Dizziness and palpitations that cannot be explained by cardiac or vestibular disease may also have a hormonal component.

Recurrent urinary tract infections are a clear example of how a problem often treated by repeated antibiotics can have a treatable underlying cause. Thinning of urethral and vaginal tissue reduces the natural barrier to infection; local oestrogen therapy can restore tissue integrity and reduce infection frequency in many patients.

Clinicians emphasise a balanced approach. HRT is an established medical therapy with potential benefits and known risks. Oral HRT carries a small increased risk of venous thromboembolism; transdermal preparations such as patches and gels are generally considered to have a lower clot risk. A personal or family history of certain hormone-sensitive cancers affects the risk–benefit assessment and may make HRT unsuitable for some women.

Guidance from practitioners recommends that women between roughly 40 and 65 who have persistent, unexplained midlife symptoms seek medical assessment rather than self-diagnosing. A careful history and targeted investigations can rule out other causes and identify those likely to benefit from hormone therapy. For localized genitourinary symptoms, topical oestrogen is often effective and carries minimal systemic exposure.

Some patients and clinicians report striking responses. In case examples cited by doctors, women who had endured months of recurrent urinary infections and local soreness saw rapid improvement after starting topical vaginal oestrogen. Others who had long-standing joint pain or cognitive changes reported improvement after systemic HRT, though outcomes vary and benefit is not guaranteed.

Clinicians and authors discussing HRT urge clear conversations about expected benefits and limitations. HRT does not reverse ageing, erase wrinkles or guarantee improved sexual function for every patient. It is not a universal cure for all midlife complaints. Shared decision-making that weighs symptom burden, medical history, personal values and alternative diagnoses remains central to appropriate care.

The recent rise in HRT prescribing and broader public discussion have prompted calls for better education for both patients and healthcare providers about the diverse ways menopause can present. Advocates say that greater awareness could reduce unnecessary antibiotic use for recurrent urinary infections, reduce misdiagnosis of conditions such as postural tachycardia syndrome or long Covid when a hormonal explanation is plausible, and help more women access appropriate therapies.

Patients are advised to discuss symptoms with a GP, who can assess the likely causes and explain treatment options and risks. Where HRT is considered appropriate, clinicians can offer topical, transdermal or oral regimens tailored to the individual. For women with complex histories, referral to menopause specialists or gynaecologists can help refine management.

Professional commentary stresses that decisions about HRT should be grounded in clinical evidence and individual circumstances rather than social media anecdotes. When used appropriately, HRT can be an effective medical treatment for a wider range of midlife symptoms than is commonly realised, but it must be prescribed after careful assessment of risks and alternatives.

Dr Ellie Cannon, a general practitioner who has written about HRT, has urged more clinicians and patients to recognise the breadth of menopausal presentations and to use HRT judiciously where indicated. Her new book aims to answer common questions and dispel myths, she said, while emphasising the importance of clinicians listening to patients and making individualized treatment decisions.